CN105169275A - 一种保肝利胆的大黄口服液及其制备方法 - Google Patents
一种保肝利胆的大黄口服液及其制备方法 Download PDFInfo
- Publication number
- CN105169275A CN105169275A CN201510657251.1A CN201510657251A CN105169275A CN 105169275 A CN105169275 A CN 105169275A CN 201510657251 A CN201510657251 A CN 201510657251A CN 105169275 A CN105169275 A CN 105169275A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- rhizoma rhei
- oral liquid
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 58
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 210000004185 liver Anatomy 0.000 title abstract description 41
- 210000000232 gallbladder Anatomy 0.000 title abstract description 22
- 230000002633 protecting effect Effects 0.000 title abstract description 4
- 240000004980 Rheum officinale Species 0.000 title abstract 4
- 235000008081 Rheum officinale Nutrition 0.000 title abstract 4
- 239000003814 drug Substances 0.000 claims abstract description 91
- 238000000605 extraction Methods 0.000 claims abstract description 30
- 210000000582 semen Anatomy 0.000 claims abstract description 25
- 230000002829 reductive effect Effects 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 16
- 239000008517 radix Trichosanthis Substances 0.000 claims abstract description 14
- 210000003038 endothelium Anatomy 0.000 claims abstract description 12
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 12
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 50
- 229940079593 drug Drugs 0.000 claims description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- 238000010438 heat treatment Methods 0.000 claims description 27
- 230000008901 benefit Effects 0.000 claims description 22
- 238000001035 drying Methods 0.000 claims description 22
- 230000002440 hepatic effect Effects 0.000 claims description 21
- 238000000108 ultra-filtration Methods 0.000 claims description 20
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 17
- 230000002279 cholagogic effect Effects 0.000 claims description 17
- 230000000844 anti-bacterial effect Effects 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 16
- 239000006228 supernatant Substances 0.000 claims description 15
- 239000010231 banlangen Substances 0.000 claims description 14
- 238000004659 sterilization and disinfection Methods 0.000 claims description 13
- 235000013305 food Nutrition 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 10
- 238000005520 cutting process Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 230000001603 reducing effect Effects 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 7
- 239000011347 resin Substances 0.000 claims description 7
- 229920005989 resin Polymers 0.000 claims description 7
- 229920001353 Dextrin Polymers 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- 238000004064 recycling Methods 0.000 claims description 6
- 238000009738 saturating Methods 0.000 claims description 6
- 230000006837 decompression Effects 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- 238000004321 preservation Methods 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 230000005070 ripening Effects 0.000 claims description 5
- 238000007789 sealing Methods 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 230000000274 adsorptive effect Effects 0.000 claims description 2
- 239000008367 deionised water Substances 0.000 claims description 2
- 229910021641 deionized water Inorganic materials 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 abstract description 8
- 230000002588 toxic effect Effects 0.000 abstract description 8
- 239000004615 ingredient Substances 0.000 abstract description 5
- 241000334160 Isatis Species 0.000 abstract description 3
- 235000013399 edible fruits Nutrition 0.000 abstract description 3
- 244000036905 Benincasa cerifera Species 0.000 abstract description 2
- 235000011274 Benincasa cerifera Nutrition 0.000 abstract description 2
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 235000014375 Curcuma Nutrition 0.000 abstract 1
- 244000164480 Curcuma aromatica Species 0.000 abstract 1
- 240000009138 Curcuma zedoaria Species 0.000 abstract 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 abstract 1
- 241000830535 Ligustrum lucidum Species 0.000 abstract 1
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 240000008042 Zea mays Species 0.000 abstract 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 abstract 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 abstract 1
- 239000012174 chinese wax Substances 0.000 abstract 1
- 235000005822 corn Nutrition 0.000 abstract 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 abstract 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract 1
- 235000019509 white turmeric Nutrition 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 73
- 210000004369 blood Anatomy 0.000 description 71
- 230000000694 effects Effects 0.000 description 50
- 230000006870 function Effects 0.000 description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 27
- 201000010099 disease Diseases 0.000 description 26
- 208000002193 Pain Diseases 0.000 description 23
- 230000036407 pain Effects 0.000 description 23
- 230000001737 promoting effect Effects 0.000 description 23
- 241000700159 Rattus Species 0.000 description 20
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 18
- 210000000941 bile Anatomy 0.000 description 18
- 210000003734 kidney Anatomy 0.000 description 18
- 210000000952 spleen Anatomy 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 150000004056 anthraquinones Chemical class 0.000 description 15
- 230000001717 pathogenic effect Effects 0.000 description 15
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 239000000463 material Substances 0.000 description 13
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 13
- 231100000614 poison Toxicity 0.000 description 13
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 13
- 206010007247 Carbuncle Diseases 0.000 description 12
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 12
- 206010010774 Constipation Diseases 0.000 description 12
- 239000010282 Emodin Substances 0.000 description 12
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 12
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 12
- 206010023126 Jaundice Diseases 0.000 description 12
- 208000004880 Polyuria Diseases 0.000 description 12
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 12
- 230000006378 damage Effects 0.000 description 12
- 230000035619 diuresis Effects 0.000 description 12
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 12
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 12
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 11
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 10
- 235000009508 confectionery Nutrition 0.000 description 10
- 210000002216 heart Anatomy 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 10
- 210000004209 hair Anatomy 0.000 description 9
- 230000023597 hemostasis Effects 0.000 description 9
- 230000008961 swelling Effects 0.000 description 9
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 244000052769 pathogen Species 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 201000000736 Amenorrhea Diseases 0.000 description 7
- 206010001928 Amenorrhoea Diseases 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 206010037660 Pyrexia Diseases 0.000 description 7
- 206010042674 Swelling Diseases 0.000 description 7
- 231100000540 amenorrhea Toxicity 0.000 description 7
- 208000001848 dysentery Diseases 0.000 description 7
- 229930182470 glycoside Natural products 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000002574 poison Substances 0.000 description 7
- 230000001681 protective effect Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 239000003440 toxic substance Substances 0.000 description 7
- 108010082126 Alanine transaminase Proteins 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 208000031971 Yin Deficiency Diseases 0.000 description 6
- 210000001015 abdomen Anatomy 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 6
- 239000010839 body fluid Substances 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- -1 dianthracene ketone glycoside Chemical class 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 150000002338 glycosides Chemical group 0.000 description 6
- 208000006454 hepatitis Diseases 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 210000005239 tubule Anatomy 0.000 description 6
- 210000003932 urinary bladder Anatomy 0.000 description 6
- IPQVTOJGNYVQEO-UHFFFAOYSA-N 9-[2-carboxy-4-hydroxy-10-oxo-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9h-anthracen-9-yl]-4-hydroxy-10-oxo-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9h-anthracene-2-carboxylic acid Chemical compound OC1C(O)C(O)C(CO)OC1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1C2C1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(OC3C(C(O)C(O)C(CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-UHFFFAOYSA-N 0.000 description 5
- 206010000087 Abdominal pain upper Diseases 0.000 description 5
- 241000700199 Cavia porcellus Species 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 206010033557 Palpitations Diseases 0.000 description 5
- 208000033809 Suppuration Diseases 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 230000035568 catharsis Effects 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 208000001780 epistaxis Diseases 0.000 description 5
- 230000004438 eyesight Effects 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 241000411851 herbal medicine Species 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 210000005229 liver cell Anatomy 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000015220 Febrile disease Diseases 0.000 description 4
- 208000034507 Haematemesis Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010067125 Liver injury Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 206010040943 Skin Ulcer Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000003187 abdominal effect Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 231100000753 hepatic injury Toxicity 0.000 description 4
- 206010019692 hepatic necrosis Diseases 0.000 description 4
- 230000007866 hepatic necrosis Effects 0.000 description 4
- 230000002443 hepatoprotective effect Effects 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 201000004792 malaria Diseases 0.000 description 4
- 239000002398 materia medica Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 4
- 238000010926 purge Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 229930186851 sennoside Natural products 0.000 description 4
- 231100000019 skin ulcer Toxicity 0.000 description 4
- 235000018553 tannin Nutrition 0.000 description 4
- 229920001864 tannin Polymers 0.000 description 4
- 239000001648 tannin Substances 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- 230000002936 tranquilizing effect Effects 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 4
- 229960001661 ursodiol Drugs 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- 230000002087 whitening effect Effects 0.000 description 4
- 208000003200 Adenoma Diseases 0.000 description 3
- 206010001233 Adenoma benign Diseases 0.000 description 3
- 102000016918 Complement C3 Human genes 0.000 description 3
- 108010028780 Complement C3 Proteins 0.000 description 3
- 206010017553 Furuncle Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000005374 Poisoning Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 208000009205 Tinnitus Diseases 0.000 description 3
- 102000003929 Transaminases Human genes 0.000 description 3
- 108090000340 Transaminases Proteins 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 229930182482 anthraquinone glycoside Natural products 0.000 description 3
- 229940098421 anthraquinone glycoside Drugs 0.000 description 3
- 150000008139 anthraquinone glycosides Chemical group 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 206010013990 dysuria Diseases 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 229940074391 gallic acid Drugs 0.000 description 3
- 235000004515 gallic acid Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 208000014617 hemorrhoid Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 239000008141 laxative Substances 0.000 description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- OISYIJRGMYJBRH-UHFFFAOYSA-N physcione Natural products COc1cc(O)c2C(=O)c3ccc(O)cc3C(=O)c2c1 OISYIJRGMYJBRH-UHFFFAOYSA-N 0.000 description 3
- 231100000572 poisoning Toxicity 0.000 description 3
- 230000000607 poisoning effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 210000004514 sphincter of oddi Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 231100000886 tinnitus Toxicity 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- 239000008812 xiaoyanlidan Substances 0.000 description 3
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- IPQVTOJGNYVQEO-LALZNDFESA-N 9-[(9r)-2-carboxy-4-hydroxy-10-oxo-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9h-anthracen-9-yl]-4-hydroxy-10-oxo-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9h-anthracene-2-carboxylic acid Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1C2[C@H]1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-LALZNDFESA-N 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 240000001579 Cirsium arvense Species 0.000 description 2
- 235000005918 Cirsium arvense Nutrition 0.000 description 2
- 206010010726 Conjunctival oedema Diseases 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 206010060710 Galactostasis Diseases 0.000 description 2
- 241000222336 Ganoderma Species 0.000 description 2
- 206010019909 Hernia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000015817 Infant Nutrition disease Diseases 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 241000241413 Propolis Species 0.000 description 2
- 241000219061 Rheum Species 0.000 description 2
- 244000299790 Rheum rhabarbarum Species 0.000 description 2
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 206010043458 Thirst Diseases 0.000 description 2
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 206010047531 Visual acuity reduced Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- WLXGUTUUWXVZNM-UHFFFAOYSA-N anthraglycoside A Natural products C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1OC1OC(CO)C(O)C(O)C1O WLXGUTUUWXVZNM-UHFFFAOYSA-N 0.000 description 2
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000002951 depilatory effect Effects 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 210000003736 gastrointestinal content Anatomy 0.000 description 2
- 230000037308 hair color Effects 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 230000002475 laxative effect Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 201000003453 lung abscess Diseases 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940069949 propolis Drugs 0.000 description 2
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
- 230000001047 pyretic effect Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- RNKMOGIPOMVCHO-SJMVAQJGSA-N 1,3,6-trigalloyl glucose Chemical compound C([C@@H]1[C@H]([C@@H]([C@@H](O)[C@H](OC(=O)C=2C=C(O)C(O)=C(O)C=2)O1)OC(=O)C=1C=C(O)C(O)=C(O)C=1)O)OC(=O)C1=CC(O)=C(O)C(O)=C1 RNKMOGIPOMVCHO-SJMVAQJGSA-N 0.000 description 1
- LAOOXBLMIJHMFO-UHFFFAOYSA-N 1-[2-(diethylamino)ethylamino]-4-methylthioxanthen-9-one;hydron;chloride Chemical compound Cl.S1C2=CC=CC=C2C(=O)C2=C1C(C)=CC=C2NCCN(CC)CC LAOOXBLMIJHMFO-UHFFFAOYSA-N 0.000 description 1
- KIZBWUUJNJEYCM-UHFFFAOYSA-N Aloeemodin-8-monoglucoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(CO)C=C1C2=O KIZBWUUJNJEYCM-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 244000139693 Arctostaphylos uva ursi Species 0.000 description 1
- 235000012871 Arctostaphylos uva ursi Nutrition 0.000 description 1
- 244000252230 Artemisia stelleriana Species 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 description 1
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 208000001378 Carbon Tetrachloride Poisoning Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 235000006693 Cassia laevigata Nutrition 0.000 description 1
- 244000025596 Cassia laevigata Species 0.000 description 1
- 208000013017 Child Nutrition disease Diseases 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010054787 Haemorrhoidal haemorrhage Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 235000001018 Hibiscus sabdariffa Nutrition 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 241001662043 Icterus Species 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 208000019637 Infantile Diarrhea Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- UGNZSMZSJYOGNX-UHFFFAOYSA-N Isoviocristine Natural products O=C1C=C(C)C(=O)C2=CC3=CC(OC)=CC(O)=C3C(O)=C21 UGNZSMZSJYOGNX-UHFFFAOYSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010050819 Musculoskeletal chest pain Diseases 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- 235000005291 Rumex acetosa Nutrition 0.000 description 1
- 240000007001 Rumex acetosella Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- 241001529553 Scoparia <angiosperm> Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- 241000257673 Strobilanthes cusia Species 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000007074 Trichomonas Vaginitis Diseases 0.000 description 1
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Natural products C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
- XAIKOVRFTSBNNU-UHFFFAOYSA-N anthracene-9,10-dione Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3C(=O)C2=C1.C1=CC=C2C(=O)C3=CC=CC=C3C(=O)C2=C1 XAIKOVRFTSBNNU-UHFFFAOYSA-N 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037358 bacterial metabolism Effects 0.000 description 1
- 235000012677 beetroot red Nutrition 0.000 description 1
- 239000001654 beetroot red Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000002185 betanin Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 238000013245 carbon tetrachloride model Methods 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000024557 hepatobiliary disease Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000000738 kidney tubule Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- HVHKMUMXERBUAN-IFADSCNNSA-N mesobilirubin IXalpha Chemical compound N1C(=O)C(CC)=C(C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C)C(=O)N\3)CC)N2)CCC(O)=O)N1 HVHKMUMXERBUAN-IFADSCNNSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000008965 mitochondrial swelling Effects 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000001543 purgative effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 201000004460 renal adenoma Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000001843 schistosomicidal effect Effects 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 229940124513 senna glycoside Drugs 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 235000003513 sheep sorrel Nutrition 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 230000033398 smooth muscle atrophy Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 230000005982 spleen dysfunction Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 210000000682 transitional epithelial cell Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000002918 waste heat Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
一种保肝利胆的大黄口服液,所述口服液包括以下重量份数的原料药:大黄10~50份,茵陈10~20份,茯苓10~20份,鱼腥草10~20份,柴胡10~20份,白芍10~20份,当归10~20份,玉米须10~20份,小蓟10~20份,虎杖10~20份,枸杞10~20份,女贞子10~20份,柏子仁10~20份,冬瓜皮10~20份,天花粉10~20份,莪术10~20份,墨旱莲10~20份,制首乌10~20份,车前子10~20份,鸡内金10~20份,生地10~20份,板蓝根10~20份。本发明大大改进中药提取技术,使得中药的有毒成分降到最低,可以使人体吸收,大大提高其利用率。
Description
技术领域
本发明涉及含有来源于植物、动物或矿物原料的医用保健品,特别涉及一种保肝利胆的大黄口服液及其制备方法。
背景技术
肝胆疾病是严重危害人类健康的常见病多发病,目前无特效药物促进肝细胞再生和防止肝细胞坏死。
大黄是多种蓼科大黄属的多年生植物的合称,也是中药材的名称。在中国地区的文献里,“大黄”指的往往是马蹄大黄。在中国,大黄主要作药用,但在欧洲及中东,他们的大黄往往指另外几个作食用的大黄属品种,茎红色,气清香,味苦而微涩,嚼之粘牙,有砂粒感。秋末茎叶枯萎或次春发芽前采挖。除去细根,刮去外皮,切瓣或段,绳穿成串干燥或直接干燥·中药大黄具有攻积滞、清湿热、泻火、凉血、祛瘀、解毒等功效。
大黄中具有致泻作用的主要成分是蒽醌甙及双蒽酮甙,其泻下作用较其相应甙元作用为强.蒽醌甙有:大黄酚-1-葡萄糖甙(Chrysophanol-1-monoglucoside)或大黄酚甙(Chrysophaein)、大黄素-6-葡萄糖甙(Emodin--6-monoglucoside)、芦荟大黄素-8-葡萄糖甙(Aloe-emodin-8-monoglucoside)、大黄素甲醚葡萄糖甙(Physcionmonoglucoside)、大黄酸-8-葡萄糖甙(Rhein-8-monoglucoside);掌叶大黄中还含有大黄素双葡萄糖甙(Emodindiglucosi-de)、芦荟大黄素双葡萄糖甙(Aloe-emodindiglucosi-de)、大黄酚双葡萄糖甙(Chrysophanoldiglucoside)。双蒽酮甙有番泻甙A、B、C、D、E、F(SennosideA、B、C、D、E、F).大黄的致泻效力与其中的结合性大黄酸含量成正比,游离的蒽醌类成分无致泻作用.番泻甙的泻下作用较蒽醌甙为强,但含量则远较后着为少。
游离型蒽醌类主要有:大黄酚(Chrysophanol)、大黄素(Emodin)、大黄素甲醚(Physcion)、芦荟大黄素(Aloe-emodin)、大黄酸(Rhein)。
大黄又含有大黄鞣酸(Rheumtannicacids)及其相关物质,如没食子酸(Gallicacid)、儿茶精(Cate-chin)、大黄四聚素(Tetrarin)。此类物质有止泻作用。
此外,大黄尚含有脂肪酸、草酸钙、葡萄糖、果糖和淀粉。
大黄根状茎含大黄酸、大黄素、大黄酚、芦荟大黄素、大黄素甲醚等游离蒽醌衍生物,均无致泻作用。另含以上物质的葡萄糖苷及番泻叶苷A、B、C等结合状蒽醌衍生物,均有致泻作用。此外尚含鞣质等。大黄根状茎及根有清热泻下、破积去瘀、抗菌消炎等作用。生用为峻下药,炮制后使用为缓下药。炒炭后又可用于止血。小剂量服用时有健胃、收敛作用。[5]
大黄含有蒽甙,故呈黄色,有通便之效。又含近40%的草酸钙,故多硬渣。其他成分还有大黄素、胶质、树脂、大黄酸、大黄泻脂和具收敛性的大黄鞣酸。
大黄的有效成分口服后,在消化道内被细菌代谢为具有生物活性的代谢产物而发挥泻下作用.亦有研究证明:大黄发挥泻下作用的另一途径是番泻甙由小肠吸收后,经肝脏转化为甙元,再刺激胃壁神经丛而引起大肠蠕动致泻,同时一部分以原型或甙元随血转运到大肠,刺激黏膜下神经丛和更深部肌肉神经丛等,使肠运动亢进,引起泻下.大黄的泻下成分能排泄于乳汁中,乳妇服用后可影响乳婴,引起婴儿腹泻.
大黄具有兴奋和抑制胃肠的双重作用,前者的物质基础是番泻甙,后者的物质基础是鞣质类,实验表明:大黄汤对小鼠的胃肠道初期呈运动亢进,后期呈运动抑制。低浓度促进,高浓度抑制。大黄中所含之鞣质对胃肠运动有抑制作用,故在产生泻下作用后可出现便秘。大剂量使用大黄(1~5g)时,产生泻下作用;小剂量使用大黄(0.05~0.3g)时则出现便秘,其机制与大黄中所含鞣质的收敛作用掩盖了含量过少的泻下成分的作用有关。
生大黄和熟大黄治疗急性上消化道出血,均有良好的止血效果,相同剂量下生大黄的作用更明显,但熟大黄对胃肠道反应小,可大剂量应用。生、熟大黄治疗急性细菌性痢疾,与西药组疗效一致,但熟大黄组副作用小,患者康复快。大黄含苦味质,服用小剂量粉剂(0.6~0.9g)可促进胃液分泌而有健胃助消化作用。
药理作用
对消化系统的影响
(1)泻下作用:作用表现:一般在服药后6~10小时排出稀便。泻下有效成分:认为主要是番泻甙类。泻下作用机理:番泻甙在肠道细菌酶的作用下分解产生大黄酸蒽酮,大黄酸蒽酮可刺激大肠粘膜,使肠蠕动增加而泻下。另外还可抑制肠细胞膜上Na+、K+-ATP酶,阻碍Na+转运,使肠内渗透压升高,保留大量水分,促进肠蠕动而泻下。
(2)利胆、保肝。
(3)促进胰液分泌、抑制胰酶活性。
(4)抗胃及十二指肠溃疡。
对血液系统的影响
(1)止血作用:特点:作用确切、见效快。止血有效成分:α-儿茶素、没食子酸。止血作用机理:促进血小板的粘附和聚集功能;增加血小板数和纤维蛋白原含量;降低抗凝血酶III活性;使受伤局部的血管收缩。
(2)降血脂:降低总胆固醇、甘油三酯、低密度脂蛋白、极低密度脂蛋白及过氧化脂质。具体方法:首先肥胖者取仰卧位,暴露腹部,先用热毛巾热敷腹部[有条件的可用红外线灯或用离子喷雾器照射腹部5-10分钟,灯距25-30cm]以感到温热舒适为宜(注意避免灼伤皮肤)。再将大黄涂布于腹部,用手掌按顺时针方向或从脐上方约三寸处起,双手上下按摩,使大黄涂布均匀,由黄棕色变为乳白色,直到被完全吸收为止,这个过程需用10-20分钟。
抗感染作用
(1)抗病原微生物作用:抗菌谱:敏感的细菌有葡萄球菌、溶血性链球菌、淋病球菌、白喉杆菌、伤寒杆菌、痢疾杆菌等。敏感的病毒有流感病毒、孤儿病毒、乙肝病毒、脊髓灰质炎病毒等。其他敏感微生物有阿米巴原虫、阴道滴虫、血吸虫及钩端螺旋体等。
抗菌有效成分:大黄酸、大黄素、芦荟大黄素。
抗菌作用机理:影响叶酸的酶系统;抑制细菌核酸和蛋白质合成;抑制细菌生物氧化酶系统;诱生干扰素。
(2)抗炎、解热作用
(3)免疫调节:蒽醌衍生物可抑制非特异性免疫功能。
(4)抗衰老抗氧化作用,国内外越来越多学者证明,大黄所含鞣质有很好的抗氧化作用。
生大黄泻下力强,故欲攻下者宜生用,入汤剂应后下,或用开水泡服;久煎则泻下力减弱。酒炙大黄泻下力较弱,活血作用好,易于瘀血证治疗。大黄炭则多用于止血。
是药三分毒,中药保健品一定要控制好剂量,使其毒性降到最低。本发明大大改进中药提取技术,使得中药的有毒成分降到最低,可以使人体吸收,大大提高其利用率。控制剂量;加强“量效关系”和“量毒关系”研究;运用现代技术,体内外方法结合评价。
发明内容
本发明所要解决的技术问题在于,肝胆疾病是严重危害人类健康的常见病多发病,目前无特效药物促进肝细胞再生和防止肝细胞坏死。是药三分毒,中药保健品一定要控制好剂量,使其毒性降到最低。本发明大大改进中药提取技术,使得中药的有毒成分降到最低,可以使人体吸收,大大提高其利用率。
为解决上述技术问题,本发明一种保肝利胆的大黄口服液,其所述口服液包括以下重量份数的原料药:大黄10~50份,茵陈10~20份,茯苓10~20份,鱼腥草10~20份,柴胡10~20份,白芍10~20份,当归10~20份,玉米须10~20份,小蓟10~20份,虎杖10~20份,枸杞10~20份,女贞子10~20份,柏子仁10~20份,冬瓜皮10~20份,天花粉10~20份,莪术10~20份,墨旱莲10~20份,制首乌10~20份,车前子10~20份,鸡内金10~20份,生地10~20份,板蓝根10~20份。
所述保肝利胆的大黄口服液,其所述口服液中各种原料药的重量份数可以为:大黄10~40份,茵陈10~15份,茯苓10~15份,鱼腥草10~15份,柴胡10~15份,白芍10~15份,当归10~15份,玉米须10~15份,小蓟10~15份,虎杖10~15份,枸杞10~15份,女贞子10~20份,柏子仁10~20份,冬瓜皮10~20份,天花粉10~20份,莪术10~20份,墨旱莲10~20份,制首乌10~20份,车前子10~20份,鸡内金10~20份,生地10~20份,板蓝根10~20份。
所述保肝利胆的大黄口服液,其所述口服液中各种原料药的重量份数还可以为:大黄10~30份,茵陈10~20份,茯苓10~20份,鱼腥草10~20份,柴胡10~20份,白芍10~20份,当归10~20份,玉米须10~20份,小蓟10~20份,虎杖10~20份,枸杞10~20份,女贞子10~15份,柏子仁10~15份,冬瓜皮10~15份,天花粉10~15份,莪术10~15份,墨旱莲10~15份,制首乌10~15份,车前子10~15份,鸡内金10~15份,生地10~15份,板蓝根10~15份。。
为解决上述技术问题,本发明提供一种保肝利胆的大黄口服液的制备方法,其所述口服液的制备步骤包括:
a.大黄的制备,作为组分1;
b.将所述其余原料药放入乙醇中加热回流提取2次,作为组分2;
c.将上述两种提取液组分1和组分2合并,浓缩后加蜂蜜或糊精调和,消毒杀菌后制备成口服液装瓶。
所述步骤a中,可以在秋末茎叶枯萎或次春发芽前采挖,除去细根,刮去外皮,切瓣或段,绳穿成串干燥或直接干燥,然后将其浸泡占其质量10倍量的乙醇中1-2小时,然后放入提取罐加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.06的浸膏,加热浓缩至膏状,静置备用,成组分1备用。
所述步骤b中,可以将所述其余原料泡入占其质量10倍量乙醇中,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.06的浸膏,加热浓缩至膏状,静置备用,成组分2。
所述步骤c中,可以将组分1和组分2合并后,置入双效真空浓缩器中,浓缩至90℃时相对密度为1.36的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含0.1g生药量;浓缩后的膏剂加蜂蜜或糊精调和,紫外线消毒杀菌后装瓶。
为解决上述技术问题,本发明再提供一种保肝利胆的大黄口服液的制备方法,制备步骤还可以为:
a.将生大黄制备加工成熟大黄,然后加水提取,作为组分1;
b.将大黄提取后残渣与所述其余原料药一起加水浸泡、提取2次作为组分2;
c.将组分1、组分2混合浓缩后加蜂蜜调和,紫外线消毒杀菌后装瓶。
所述步骤a中,可以在秋末茎叶枯萎或次春发芽前采挖,除去细根,刮去外皮,切瓣或段,绳穿成串干燥或直接干燥,取切成小块的生大黄,用黄酒拌匀,放蒸笼内蒸制,或置罐内密封,坐水锅中,隔水蒸透,取出晒干,按上法反复蒸制2~3次者,干燥成熟大黄,然后将干燥后的熟大黄片加水,然后放入提取罐加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.06的浸膏,作为组分1;所述步骤b中,可以将提取的熟大黄渣滓与所述其余原料一起放入占其质量5-10倍量水中,浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,将2次提取液合并静置,减压并浓缩至药液浓度为0.6g生药/mL,抽滤后,滤液的相对密度约为20℃时1.08;减压至0.03-0.08MPa,温度保持在60-80℃,浓缩至相对密度为1.20,温度至60℃-70℃的浸膏,作为组分2。
所述步骤c中,可以将组分1与组分2混合后放入减压浓缩罐内,减压回收乙醇,浓缩至药液浓度为0.1g生药/mL,抽滤至滤液的相对密度为20℃时1.06;上述滤液经体积为10L的大孔吸附树脂柱吸附后,用10倍树脂柱体积的去离子水或蒸馏水洗脱,再用5倍树脂柱体积的95%乙醇洗脱,收集乙醇洗脱液,去除溶剂,再调和蜂蜜,紫外线消毒杀菌后装瓶。
生大黄泻下力强,故欲攻下者宜生用,入汤剂应后下,或用开水泡服;久煎则泻下力减弱。酒炙大黄泻下力较弱,活血作用好,易于瘀血证治疗。大黄炭则多用于止血。肝胆疾病是严重危害人类健康的常见病多发病,目前无特效药物促进肝细胞再生和防止肝细胞坏死。本发明对CCL4引起的急性肝损伤有明显的保护作用,有使SGOT显著降低作用。血清转氨酶升高主要反映肝细胞变性、坏死,细胞膜通透性升高,使肝细胞内GPT、GOT释放入血所致。有文献报道由CCL4中毒引起的动物SGPT、SGOT升高与肝细胞损伤程度呈粗略平行关系。本发明有选择性地降低SGOT作用,大剂量使肝脏指数减少,也说明本药有较好的保肝作用。
具体实施方式
大黄为常用中药,具有泻热通肠、凉血解毒,逐瘀通经的功效。用于实热便秘,积滞腹痛,泻痢不爽,湿热黄疸,血热吐衄,目赤,咽肿,肠痈腹痛,痈肿疔疮,瘀血经闭,跌扑损伤。熟大黄泻下力缓,泻炎解毒。用于火毒疮疡。大黄炭凉血化瘀止血。用于血热有瘀出血症。现代医学证明,该品具有导泻、利胆、保肝、抗溃疡、抗菌、抗病毒等作用。
大黄素(emodin)在进行二年的口饲大黄素实验研究中,大黄素在280,830,2500ppm食物含量中,对F344/N雄性大鼠无致癌性,对F344/N雌性大鼠有可能诱发Zymmbal腺癌的发生,对B6C3F1雄性小鼠,有可能发生少见的肾小管赘生物(renaltubleneoplasms),但发生率较低;大黄素在312,625,1250ppm食物含量下,B6C3F1雌性小鼠未发现有致癌性的证据。大黄素可导致雄性大鼠肾小管透明滴(renaltublehyalinedroplets)和染色(pigmentation)的发生率增加,可导致雌性大鼠肾小管透明滴的发生率增加,可导致雌雄大鼠肾小管染色的严重性增大,可导致雌雄小鼠肾小管染色的发生率增加,导致雌性小鼠肾病的发生率增加。
蒽醌(Anthraquinone)通过两年给药研究表明,基于肾小管腺瘤(renaltubuleadenoma)、肾脏和膀胱迁移性上皮细胞乳头瘤(transitionalepithelialpapillomas)的发生率增加,表明蒽醌对雄性F344/N大鼠具有致癌性。肝细胞瘤的发生与给予蒽醌有关。基于肾小管腺瘤的发生率增加,表明蒽醌对雌性F344/N大鼠具有致癌性。膀胱移行性上皮细胞乳头瘤或/和癌的发生率以及在雌性大鼠出现的肝细胞腺瘤均与使用蒽醌有关。有明显的证据表明蒽醌可增加雄性和雌性B6C3F1小鼠肝癌的发生率。在雄性和雌性小鼠上的甲状腺滤泡细胞瘤(Thyroidglandfollicularcellneoplasms)的产生可能与蒽醌的使用有关。使用蒽醌两年,可引起雄性和雌性大鼠肾、肝、脾、骨髓非肿瘤性损害增加,可引起雄性和雌性小鼠肝、膀胱和脾非肿瘤性损害增加,也可导致雄性小鼠甲状腺和肾脏的非肿瘤性损害。使用蒽醌可使雄性和雌性大鼠单核细胞性白血病的发生率减少。
大黄一般被认为毒性较低,临床应用比较安全。但服用过量可引起中毒,尤其是后下大黄毒性较大,可起恶心、呕吐、头昏、腹绞痛、黄疸等。曾有报道,30名受试者每日服大黄3次,每次3g,共5日,所有受试者均产生一系列胃肠反应,主要表现为腹泻、腹痛、呕吐、恶心、肠鸣,其中3例因严重腹泻、腹痛、呕吐而被迫卧床休息,经对症处理后缓解。国外曾报道1例长期服蒽醌类泻药,导致结肠膨胀,手术切除结肠标本可见变黑,肌层神经元消失,平滑肌萎缩。长期服用蒽醌类泻药还可能引起肝硬化和电解质紊乱(低血钾)。大黄的临床毒副作用除主要引起消化系统症状外,还可引起动物实验结果一致的免疫抑制作用。报道正常人(男12,女11),年龄自24-66岁,分3组每晨服大黄醇提片9片(每片相当于原生药1g)共服7日,IgA、IgG、IgM均较服药前降低,白细胞移动抑制试验降低(P<0.05),C3补体和总补体也降低(P<0.001),但淋巴细胞转化试验无变化。服5片组在dl4所测定的IgA、IgG、IgM均降低(P<0.02-0.001),C3补体及总补体也降低(P<0.05),而淋巴细胞转化率升高(P<0.001)。服2.5片组在dl4与服药比较:IgA、IgG、IgM均降低(P<0.05-0.001)、C3补体与补体也降低(P<0.001),而淋巴细胞转化率上升(P<0.05)。然而这些数值的变化均在正常范围之内,因而没有重要的临床意义。提示短期服用较大量的大黄不会明显降低免疫功能。
茯苓味甘、淡、性平,入药具有利水渗湿、益脾和胃、宁心安神之功用。现代医学研究:茯苓能增强机体免疫功能,茯苓多糖有明显的抗肿瘤及保肝脏作用。茯苓性味甘淡平,入心、肺、脾经。具有渗湿利水,健脾和胃,宁心安神的功效。可治小便不利,水肿胀满,痰饮咳逆,呕逆,恶阻,泄泻,遗精,淋浊,惊悸,健忘等症。茯苓之利水,是通过健运脾肺功能而达到的,与其它直接利水的中药不同。用于脾虚泄泻,带下茯苓既能健脾,又能渗湿,对于脾虚运化失常所致泄泻、带下,应用茯苓有标本兼顾之效,常与党参、白术、山药等配伍。有可用为补肺脾,治气虚之辅佐药。
茵陈清热利湿;退黄。主治:黄疸、小便不利、湿疮瘙痒、传染性黄疸型肝炎。有利胆,保护肝功能,解热,抗炎,降血脂,降压,扩冠等作用.茵陈有显著的保肝作用,对甲,乙型肝炎,黄疸型肝炎,有显著的疗效。有利胆,促进胆汁分泌,增加胆汁中胆酸和胆红素排出的作用.能增加心脏冠脉血流量,改善微循环,并有降血压,降血脂,抗凝血,利尿解热平喘,驱除蛔虫及抑制多种致病性皮肤真菌与细菌的作用。
鱼腥草味辛,性寒凉,归肺经。能清热解毒、消肿疗疮、利尿除湿、清热止痢、健胃消食,用治实热、热毒、湿邪、疾热为患的肺痈、疮疡肿毒、痔疮便血、脾胃积热等。现代药理实验表明,本品具有抗菌、抗病毒、提高机体免疫力、利尿等作用。《滇南本草》:治肺痈咳嗽带脓血,痰有腥臭,大肠热毒,疗痔疮。《本草纲目》:散热毒痈肿,疮痔脱肛,断店疾,解硇毒。《医林纂要》:行水,攻坚,去瘴,解暑。疗蛇虫毒,治脚气,溃痈疽,去瘀血。
白芍苦,微寒。归肝经。主治功效:清热凉血;活血祛瘀。主温毒发斑;吐血衄血;肠风下血;目赤肿痛;痈肿疮疡;闭经;痛经;崩带淋浊;瘀滞胁痛;疝瘕积聚;跌扑损伤。用于温毒发斑,吐血衄血,目赤肿痛,肝郁胁痛,经闭痛经,症瘕腹痛,跌扑损伤,痈肿疮疡。《本经》:主邪气腹痛,除血痹,破坚积,寒热疝瘕,止痛,利小便,益气。《别录》:通顺血脉,缓中,散恶血,逐贼血,去水气,利膀胱大小肠,消痈肿,时行寒热,中恶腹痛,腰痛。《药性论》:治肺邪气,腹中疞痛,血气积聚,通宣脏腑拥气,治邪痛败血,主时疾骨热,强五脏,补肾气,治心腹坚胀,妇人血闭不通,消瘀血,能蚀脓。
玉米须味甘、淡,性平。有利尿消肿;清肝利胆的功效。主水肿,小便淋沥,黄疸,胆囊炎,胆结石,高血压,糖尿病,乳汁不通。《滇南本草》:宽肠下气。治妇人乳结,乳汁不通,红肿疼痛,怕冷发热,头痛体困。《岭南采药录》:和猪肉煎汤治糖尿病。又治小便淋沥砂石,苦痛不可忍,煎汤频服。
虎杖微苦,微寒。归肝、胆、肺经。功能与主治清热解毒,利胆退黄,祛风利湿,散瘀定痛,止咳化痰。用于关节痹痛,湿热黄疸,经闭,产后瘀血不下,癓瘕,咳嗽痰多,水火烫伤,跌打损伤,痈肿疮毒。虎杖煎剂作用,对外伤出血有明显止血作用,内服对上消化道出血也有止血作用。《日华子本草》:治产后恶血不下,心腹胀满。排脓,主疮疖痈毒,妇人血晕,扑损瘀血,破风毒结气。《滇南本草》:攻诸肿毒,止咽喉疼痛,利小便,走经络。治五淋白浊,痔漏,疮痈,妇人赤白带下。
墨旱莲菊科,一年生草本植物。直立,具匍匐茎;叶对生,披针形;头状花序,腋生或顶生,花白色;瘦果黑色。全国广布种。常见于田梗,沟溪边湿地。全草药用,能收敛、止血、补肝肾之功效。滋补肝肾、凉血止血,可治各种吐血,肠出血等症。捣汁涂眉发,能促进毛发生长,内服有乌发、黑发功效。《唐本草》说,墨旱莲“主血痢,针灸疮发,洪血不可止者敬之”《日华子本草》中也说,墨旱莲可以“排脓,止血,通小肠,敷一切疮并蚕瘑”。
莪术根茎称“莪术”,供药用,主治“气血凝滞,心腹胀痛,症瘕,积聚,宿食不消,妇女血瘀经闭,跌打损伤作痛。”块根称“绿丝郁金”,有行气解郁,破瘀,止痛的功用。辛、苦,温。归肝、脾经。破血行气,消积止痛。用于血瘀腹痛、肝脾肿大、心腹胀痛,积聚,妇女血瘀经闭,跌打损伤作痛饮食积滞。行气止痛,破血消积:用于气滞血瘀之经闭、胸胁痛、腹痛及症瘕肿块等。常配三棱。
柴胡性味苦、微寒,归肝、胆经。有和解表里,疏肝升阳之功效。用于感冒发热、寒热往来、疟疾、肝郁气滞、胸肋胀痛、脱肛、子宫脱垂、月经不调。和解表里,疏肝解郁,升阳举陷,退热截疟。《本经逢原》:“柴胡,小儿五疳羸热,诸疟寒热,成宜用之。痘疹见点后有寒热,或胁下疼热,于透表药内用之,不使热留少阳经中,则将来无咬牙之患。”
当归,其味甘而重,故专能补血,其气轻而辛,故又能行血,补中有动,行中有补,诚血中之气药,亦血中之圣药。大约佐之以补则补,故能养营养血,补气生精,安五脏,强形体,益神志,凡有形虚损之病,无所不宜。佐之以攻则通,故能祛痛通便,利筋骨,治拘挛、瘫痪、燥、涩等证。营虚而表不解者,佐以柴、葛、麻、桂等剂,大能散表卫热,而表不敛者,佐以大黄之类,又能固表。惟其气辛而动,故欲其静者当避之,性滑善行,大便不固者当避之。凡阴中火盛者,当归能动血,亦非所宜,阴中阳虚者,当归能养血,乃不可少。
枸杞既是传统名贵中药材,又是一种营养滋补品,最适于与灵芝搭配服用。在卫生部公布的63种药食两用的名单中,名列榜首。[1]作为传统中药,枸杞性平味甘,具有滋补肝肾、益精明目、润肺的功效,与灵芝搭配可防止百病。通过化学成分分析,枸杞的果实检测出含有丰富的天然胡萝卜素、维生素C、枸杞蛋白多糖、甜菜碱、亚油酸以及铁、磷、钙等营养成分,有补虚安神、明目祛风、滋肾润肺以及护肝抗肿瘤等作用。
板蓝根为十字花科植物菘蓝的干燥根,通常在秋季进行采挖,炮制后可入药。在中国各地均产。板蓝根分为北板蓝根和南板蓝根,北板蓝根来源为十字花科植物菘蓝(IsatistinctoriaL.)的根;南板蓝根为爵床科植物马蓝(Baphicacanthuscusia(Nees)Brem.)的根茎及根。其性寒,味先微甜后苦涩,具有清热解毒、预防感冒、利咽之功效。主要用于治疗温毒发斑、舌绛紫暗、烂喉丹痧等疾病。
女贞子用于肝肾阴虚的目暗不明,视力减退,须发早白,腰酸耳鸣及阴虚发热等。本品能补肝肾阴,但药力平和,须缓慢取效。治目暗不明,常配熟地,枸杞等同用,治须发早白,常配桑葚同用,阴虚发热,常配地骨皮。肝肾阴虚,头昏目眩、遗精耳鸣、腰膝酸软,须发早白,冠心病、高脂血症、高血压、慢性肝炎。对肝脏的保护作用研究认为,女贞子含有齐墩果酸,给大鼠皮下注射,可降低血清谷丙转氨酶,对四氯化碳诱发的肝损伤有明显保护作用,并能促进肝细胞再生.齐墩果酸亦可使肝内甘油三酯蓄积减少、肝细胞变性坏死明显减轻、糖原蓄积增加、血清γ球蛋白下降;超微结构可见肝细胞内线粒体肿胀与内质网囊泡变性减轻、肝组织间质炎症反应减弱。
柏子仁性平味甘,心、肾、大肠经。具养心安神、润肠通便的功效。治惊悸、失眠、遗精、盗汗、便秘等症,能养心安神,润肠通便。用于虚烦不眠,心悸怔忡,肠燥使秘等症。《药品化义》:柏子仁,香气透心,体润滋血。同茯神、枣仁、生地、麦冬,为浊中清品,主治心神虚怯,惊悸怔仲,颜色憔悴,肌肤燥痒,皆养心血之功也。又取气味俱浓,浊中归肾,同熟地、龟版、枸杞、牛膝,为封填骨髓,主治肾阴亏损,腰背重病,足膝软弱,阴虚盗汗,皆滋肾燥之力也。味甘亦能缓肝,补肝胆之不足,极其稳当,但性平力缓,宜多用之为妙。
中药何首乌有生首乌与制首乌之分,直接切片入药为生首乌,用黑豆煮汁拌蒸后晒干入药为制首乌。二者的功用有所不同:生首乌功能解毒、消痈、润肠通便,常用于治疗瘰疬疮痈、风疹瘙痒、肠燥便秘;制首乌功能补肝肾、益精血、乌须发、强筋骨,用于血虚萎黄、眩晕耳鸣、须发早白、腰膝酸软、肢体麻木、崩漏带下、久疟体虚等。本发明所采用的制首乌是补肾益肾的佳品。
车前子本品性味甘寒,入肾、膀胱、肝、肺经,功能利水通淋、渗湿止泻、清肝明目、清热化痰,为常用药材。利水,清热,明目,祛痰。治小便不通,淋浊,带下,尿血,暑湿泻痢,咳嗽多痰,湿痹,目赤障翳。《本经》:″主气癃、止痛,利水道小便,除湿痹。″《本草经集注》:″主虚劳。″《别录》:″男子伤中,女子淋沥,不欲食。养肺强阴益精。明目疗赤痛。″
小蓟:又名,刺儿菜,学名Cirsiumsetosum,甘、苦,凉。归心、肝经。功能与主治:凉血止血,祛瘀消肿。用于衄血,吐血,尿血,便血,崩漏下血,外伤出血,痈肿疮毒。小蓟能收缩血管、缩短凝血时间。对肺炎双球菌、溶血性链球菌、白喉杆菌、伤寒村菌、绿脓杆菌、痢疾杆菌、金黄色葡萄球菌等均有抑制作用。煎剂或酊剂对兔子宫有兴奋作用。此外,尚有利胆、降低血中胆固醇的作用。
鸡内金归脾、胃、小肠、膀胱经。健胃消食,涩精止遗,通淋化石。用于食积不消,呕吐泻痢,小儿疳积,遗尿,遗精,石淋涩痛,胆胀胁痛。《滇南本草》:宽中健脾,消食磨胃。治小儿乳食结滞,肚大筋青,痞积疳积。
生地:生地也叫生地黄,玄参科多年生草本植物地黄RehmanniaglutinosaLibosch.的新鲜或干燥的块根。清热、生津、润燥、滑肠、破瘀、生新、止痛、调经、金疮瘀、凉血、止血;鲜地黄和生地黄的作用是有所不同的。鲜地黄清热生津,可以止血和凉血,经常是用于热病伤阴,吐血、咽喉肿痛、舌绛烦渴、发斑发疹以及衄热等病症。相对于鲜地黄,生地黄是凉血清热,也可以生津,还可以养阴,多用于治疗阴虚内热、骨蒸劳热、舌绛烦渴、发斑发疹等问题。生地性寒,功能为滋阴补肾。不只生津止渴和凉血清热,还对血崩、月经不调、胎动不安、便秘等有作用,凡是血分有热伤阴的人,都可以经常服用。如果想要治疗温热病,可以用生地做清营汤;如果是治疗温病的后期,由于余热还没消尽,应该把生地用来煮青蒿鳖甲汤;另外,针对血热毒盛,斑疹紫黑,温热病严重热入营血的症状,可以服用生地制成的四生丸;一般要养阴生津来治疗内热消渴和便秘的,应该食用生地煮的曾液汤。
冬瓜皮,中药名。为葫芦科植物冬瓜Benincasahispida(Thunb.)Cogn.的干燥外层果皮。食用冬瓜时,洗净,削取外层果皮,晒干。味甘,性凉。归脾、小肠经。利尿消肿。用于水肿胀满,小便不利,暑热口渴,小便短赤。
天花粉,中药名。《本草正义》:药肆之所谓天花粉者,即以萎根切片用之,有粉之名,无粉之实。天花粉为葫芦科植物栝蒌的根,是一种中药,为清热泻火类药物,其具体功效是清热泻火,生津止渴,排脓消肿。主治:治热病口渴、消渴、黄疸、肺燥咳血、痈肿、痔痿。对于治疗糖尿病,常用它与滋阴药配合使用,以达到标本兼治的作用。
本发明具体实施方式
具体实施例1:
大黄在秋末茎叶枯萎或次春发芽前采挖,除去细根,刮去外皮,切瓣或段,绳穿成串干燥或直接干燥,将其浸泡乙醇中1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.06的浸膏,加热浓缩至膏状,静置备用,成组分1。
将其余原料药茵陈,茯苓,鱼腥草,柴胡,白芍,当归,玉米须,小蓟,虎杖,枸杞,女贞子,柏子仁,冬瓜皮,天花粉,莪术,墨旱莲,制首乌,车前子,鸡内金,生地,板蓝根,放入10倍量乙醇中,浸泡1-2小时,加热提取2次,每次1-2小时,合并提取液,静置后去上清液,然后放入减压浓缩罐内,减压回收乙醇,浓缩至药液浓度为0.6g生药/mL,抽滤至滤液的相对密度为80℃时1.06的浸膏,成为组分2。
将组分1和组分2合并后置入双效真空浓缩器中,浓缩至90℃时相对密度为1.36的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含0.1g生药量;浓缩后的膏剂加糊精调和,紫外线消毒杀菌后装瓶。
具体实施例2:
在秋末茎叶枯萎或次春发芽前采挖,除去细根,刮去外皮,切瓣或段,绳穿成串干燥或直接干燥,取切成小块的生大黄,用黄酒拌匀,放蒸笼内蒸制,或置罐内密封,坐水锅中,隔水蒸透,取出晒干,按上法反复蒸制2~3次者,干燥成熟大黄5000g后,将其泡入10倍量乙醇中,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.06的浸膏,加热浓缩至膏状,静置备用,成组分1。
将茵陈1500g,茯苓1500g,鱼腥草1500g,柴胡1500g,白芍1500g,当归1500g,玉米须1500g,小蓟1500g,虎杖1500g,枸杞1500g,女贞子1500g,柏子仁1500g,冬瓜皮1500g,天花粉1500g,莪术1500g,墨旱莲1500g,制首乌1500g,车前子1500g,鸡内金1500g,生地1500g,板蓝根1500g,将其余原料药的药放入10倍量乙醇中,浸泡1-2小时,加热提取2次,每次1-2小时,合并提取液,静置后去上清液,然后放入减压浓缩罐内,减压回收乙醇,浓缩至药液浓度为0.6g生药/mL,抽滤至滤液的相对密度为20℃时1.06的浸膏,成为组分2。
将组分1和组分2合并后置入双效真空浓缩器中,浓缩至90℃时相对密度为1.35的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含0.1g生药量;浓缩后的膏剂加糊精调和,紫外线消毒杀菌后装瓶。
具体实施例3:在秋末茎叶枯萎或次春发芽前采挖,除去细根,刮去外皮,切瓣或段,绳穿成串干燥或直接干燥,取切成小块的生大黄,用黄酒拌匀,放蒸笼内蒸制,或置罐内密封,坐水锅中,隔水蒸透,取出晒干,按上法反复蒸制2~3次者,干燥成熟大黄4500g后,然后将干燥后的熟大黄片加水,然后放入提取罐加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.06的浸膏,作为组分1,将所述其余原料将茵陈1200g,茯苓1100g,鱼腥草1100g,柴胡1200g,白芍1200g,当归1200g,玉米须1200g,小蓟1200g,虎杖1200g,枸杞1100g,女贞子1200g,柏子仁1100g,冬瓜皮1100g,天花粉1100g,莪术1200g,墨旱莲1100g,制首乌1100g,车前子1100g,鸡内金1100g,生地1100g,板蓝根1200g,放入5-10倍量水中,浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,将2次提取液合并静置,减压回收乙醇,并浓缩至药液浓度为0.6g生药/mL,抽滤后,滤液的相对密度约为20℃时1.08;减压至0.03-0.08MPa,温度保持在60-80℃,浓缩至相对密度为1.20,温度至60℃-70℃的浸膏,作为组分2。将组分1组分2混合置入双效真空浓缩器中,浓缩至90℃时相对密度为1.05的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含0.1g生药量;浓缩后的膏剂加组分1的精油然后加蜂胶调和,紫外线消毒杀菌后装瓶。
具体实施例4:在秋末茎叶枯萎或次春发芽前采挖,除去细根,刮去外皮,切瓣或段,绳穿成串干燥或直接干燥,取切成小块的生大黄,用黄酒拌匀,放蒸笼内蒸制,或置罐内密封,坐水锅中,隔水蒸透,取出晒干,按上法反复蒸制2~3次者,干燥成熟大黄4500g后,泡入10倍量乙醇中,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.06的浸膏,加热浓缩至膏状,静置备用,成组分1。将茵陈1100g,茯苓1100g,鱼腥草1100g,柴胡1200g,白芍1200g,当归1100g,玉米须1200g,小蓟1200g,虎杖1200g,枸杞1100g,女贞子1200g,柏子仁1100g,冬瓜皮1100g,天花粉1100g,莪术1200g,墨旱莲1100g,制首乌1100g,车前子1200g,鸡内金1100g,生地1200g,板蓝根1200g,将所述原料药放入粉碎机粉碎后,将颗粒物放入乙醇中加热回流提取2次,每次1~2小时,将2次提取液合并静置;将上述乙醇提取过的药渣加10倍量水加热回流提取2次,每次1~2小时,将2次提取液合并静置,将上述两种提取液合并,作为组分2;合并组分1组分2减压浓缩相对密度为80℃时1.36的滤液,回收乙醇,调入蜂胶,紫外线杀菌后装瓶。
试验例1:本发明急性毒性试验
一、试验材料:
动物:昆明种小鼠,体重21-24g,雌雄各半,山东大学生物试验室育种。药物:本发明口服液(按实施方法2制备)。
二、方法:
1、LD50计算:采用改良寇氏法,将小鼠随机分成5组,每组10只,雌雄各半,将栓剂溶解,配成最大浓度,按小鼠最大允许容量给药,所给剂量按生药量依次为18,14.4,11.5,9.2,7.4(g.kg-1),在动物禁食(不禁水)18小时后,一日内分两次给药(间隔半小时),每次0.5ml,观察动物死亡情况。
2、最大耐受剂量测定(MTD值):取小鼠20只,雌雄各10只。将栓剂加蒸馏水溶解,配成最高浓度,按动物的最大耐受量,以注射灌喂器能抽动为准。在动物禁食(不禁水)18小时后,一日内分两次给药(间隔半小时),每次0.5ml(每ml含生药0.36g),总药量为18g生药/kg.d,相当临床成人50Kg体重用量的300倍。给药后连续观察7天。
三、试验结果:
在LD50计算中当用最大允许浓度和最大允许容量给予小鼠时(18g/Kg.d),未见小鼠死亡,即未测出LD50,只可求最大耐受剂量,在7天观察期中,动物其食欲、活动、毛色、精神状态等皆正常,发育正常,未见有死亡。即选用相当于临床剂量的300倍药量,并无不良反应发生,表明急性毒性极小,MTD>18g/Kg.d。
试验例2:本发明急性皮肤刺激试验报告
1、实验目的:检测本发明对实验动物皮肤的刺激/腐蚀作用和强度
2、材料和方法:
2.1.受试物:本发明口服液(按实施例方法2制得)
2.2.实验动物:壹级大耳白种家兔,10只,雌性,体重2.1-2.3kg;由青岛大学医学院生物系实验动物中心提供;
2.3.试验方法:
选用皮肤完好的健康家兔10只,于试验前24小时将其背部脊柱两侧被毛剪掉,去毛面积左、右各约4cm×4cm。试验时取受试物0.2ml涂于2.5cm×2.5cm的二层纱布上,敷贴于一侧去毛皮肤表面,油纸覆盖,胶布固定。另一侧皮肤作为空白对照。封闭4小时后,去除覆盖物,并用温水清洗去残留受试物,于去除受试物后的1、24和48小时观察涂抹部位皮肤反应,并评分。
3、实验结果:实验动物皮肤未出现任何红斑,红肿,发炎现象。
4、小结:根据《(消毒技术规范》(1999)中皮肤刺激反应评分标准判定,本发明对动物皮肤刺激强度属无刺激性。
实施例3:长期毒性实验资料
1、实验方法
将豚鼠随机份成4组,每组15只。在豚鼠背部脊柱两侧将脱毛剂均匀涂上,使其脱毛范围约40平方厘米。洗净脱毛剂,观察24小时后每组豚鼠分别涂本发明口服液溶液0.2、0.4和0.8ml,分别含生药92、184和368mg,另一组涂溶媒0.8ml每日二次,连续30天,观察豚鼠的一般情况,实验结束后处死动物进行血液学、血液生化及病理学检查。
2、结果
上述三组用药豚鼠躯干去毛区,未见局部皮肤有水肿、充血、红斑、出血点及溃疡。用药组与对照组动物毛发色泽、摄食、四肢活动等对照组无明显差异,血液生化检查,用药组与对照组均在正常范围。病理组织学检查,实验各组心、肝、肾及局部皮肤均未见明显病变。提示,本发明中药口服液长期用药对局部皮肤及全身重要脏器均未见明显的毒性作用。
试验结果表明:本发明口服液实验安全。该药对乙型链球菌、金黄色葡萄球菌、大肠杆菌的最小抑制浓度为1∶150,淋球菌为1∶150,白色念珠菌为1∶300,对1∶20稀释度时的杀灭时间为5分钟,1∶50时为10分钟,1∶100时为20分钟,1∶200时为40分钟,1∶400时为8小时。
药理学实验:
大黄对正常小鼠由四氯化碳引起的肝损伤有明显保护作用,表现为SGOT显著降低,使肝体比降低(大剂量)。对正常大鼠有显著的利胆作用,胆汁流量增加持续2h。熊去氧胆酸流量增加持续1小时。胆汁中胆固醇、胆红素给药前和给药后组间比较未见显著差异性。为此我们进行了实验研究。
1、材料与方法
药物:本发明提醇沉液的制备:取一定量本发明原料药,水煎两次,水浴上浓缩至一定体积后加95乙醇沉淀杂质,过液,滤液回收乙醇。配成100%浓度。
对照组为白云山消炎利胆片,国药准字Z44022243。熊去氧胆酸为日本三菱化成生产。
动物ICR小鼠,SD大鼠均由本院动物研究室提供。
1.1对四氯化碳引起的小鼠肝损伤的保护作用:雄性小鼠78只,体重18-23g,按体重随机分层分成六组,每组13只。本发明3个剂量组2.5g/kg、5.0g/kg、10.0g/kg,阳性对照药白云山消炎利胆片10g/kg,模型组,水对照组每天灌胃给药一次,连续6d,于第六天给药后1h除水对照组外其余各组均皮下注射0.15的四氯化碳菜油5ml/kg。16h后摘眼球取血用北京化工厂产的试剂盒测定血清SGPT、SGOT。解剖出肝脏称重,根据处死时体重计算每只小鼠的肝体比、数据以均值士标准差表示,组间进行t检验。
1.2对正常大鼠胆汁流量的影响1.2.1
胆汁流量的测定:取大鼠60只,雄性,体重250~350g,称重随机分成五组,每组12只,实验前禁食12h,不禁水。实验以10%乌拉坦1.0g/kg腹腔注射麻醉,仰位固定于手术台,沿腹正中线切开腹壁,找出十二指肠,在降部肠系膜中找到白色有韧性的胆管,在其下穿二根丝线,结扎乳头部,向肝脏方向作“V”形切口,插入硬质塑料管,结扎固定,即可见有淡黄绿色胆汗流出,试管收集胆汁,术后以盐水纱布覆盖腹腔,待稳定1h后,先收集30min的胆汁,作为给药前的基础值,然后分组给药(经十二指肠)。本发明3个剂量组2.5g/kg、5.0g/kg、10.0g/kg,水对照组,阳性药熊去氧胆酸0.5g/kg。给药后每隔30min收集测量1次胆汁。共4h。
1.2.2胆汁成分的测定:将给药前,给药后4h收集的胆汁测定胆红素(伊利康生物技术有限公司生产,咖啡因法)。胆固醇含量测定用东欧生物工程公司生产的试剂盒,酶法测定。
2实验结果
2.1对四氯化碳引起的小鼠肝损伤的保护作用:四氯化碳引起的SGPT、SGOT显著升高P<0.01,说明造型成功。本发明使SGOT显著降低三个剂量组均P<0.05,本发明对SGPT无明显影响。白云山消炎利胆片使SGPT、SGOT显著降低(P-~0.05)。泽兰10g/kg组使肝体比显著低于四氯化碳模型组。详见表1。
表1本发明对四氯化碳中毒小鼠血清转氨酶的影响(X±S)
注:组间进行t检验,与四氯化碳组比*P<0.05,**P<0.01
2.2对正常大鼠胆汁流量的影响:本发明2.5g/kg组使正常大鼠胆汁流量增加,持续2h,以给药后的30min增加最显著<0.05)。5.0g/kg组给药2h各时相都显著增加<0.05.10.0g/kg组给药后90min内各时相都比对照组显著升高(P<0.01,P<0.05)。阳性药熊去氧胆酸也使流量增加,持续1h。P<0.05详见表2。
表2本发明对麻醉大鼠胆汁流量的影响(X±S)
注t以给药前流量为100%,组问进行t检验,与对照组比*P<0.05,**P<0.01.本发明给药前、给药后涓定胆汁中胆红素和胆同醇含量与对照组相比未见显著差异。详见表3。
表3本发明对大鼠胆汁中胆固醇、胆红素排出量的影响(X±S)
讨论:
生大黄泻下力强,故欲攻下者宜生用,入汤剂应后下,或用开水泡服;久煎则泻下力减弱。酒炙大黄泻下力较弱,活血作用好,易于瘀血证治疗。大黄炭则多用于止血。肝胆疾病是严重危害人类健康的常见病多发病,目前无特效药物促进肝细胞再生和防止肝细胞坏死。我们的实验已经证明本发明有良好抗实验性肝硬变作用。本实验表明本发明对CCL4引起的急性肝损伤有明显的保护作用,有使SGOT显著降低作用。血清转氨酶升高主要反映肝细胞变性、坏死,细胞膜通透性升高,使肝细胞内GPT、GOT释放入血所致。有文献报道由CCL4中毒引起的动物SGPT、SGOT升高与肝细胞损伤程度呈粗略平行关系。本发明有选择性地降低SGOT作用,大剂量使肝脏指数减少,也说明本药有较好的保肝作用。
大黄在增加胆汁分泌的同时,还可降低狗总管奥狄氏括约肌张力。给狗以2ml/kg体重行十二指肠灌注竺。20%的大黄煎剂1小时后观察对肝胆汁流出量及对奥狄氏括约肌灌流量的影响,结果表明:大黄能利胆.增加胆汁流量;促进排胆松驰奥狄氏括约肌;促进胆内容物(包括郁结的胆汁沉积的胆泥,甚则小的结石)的排出,进而降低胆道内压力,缓解胆绞痛。
传统医学认为肝胆系的炎症、结石主要是湿热邪毒播体内而致.有人分析100例肝炎病人的肝穿病理结果并结合中医辨证分型得出急性黄疽型肝炎100%属中医湿热的结论.所以清除湿热邪毒用通腑泻下.利湿解毒是常之治则.大黄则是常用乙药。以大黄为主的复方治疗急性肝炎184例.近期治愈率79.5%,表明大黄用于肝胆疾患,用于低黄疽指数、缩短病程、减轻症状以及恢复肝功能确有显著疗效。
Claims (10)
1.一种保肝利胆的大黄口服液,其特征在于,所述口服液包括以下重量份数的原料药:大黄10~50份,茵陈10~20份,茯苓10~20份,鱼腥草10~20份,柴胡10~20份,白芍10~20份,当归10~20份,玉米须10~20份,小蓟10~20份,虎杖10~20份,枸杞10~20份,女贞子10~20份,柏子仁10~20份,冬瓜皮10~20份,天花粉10~20份,莪术10~20份,墨旱莲10~20份,制首乌10~20份,车前子10~20份,鸡内金10~20份,生地10~20份,板蓝根10~20份。
2.根据权利要求1所述保肝利胆的大黄口服液,其特征在于,所述口服液中各种原料药的重量份数为:大黄10~40份,茵陈10~15份,茯苓10~15份,鱼腥草10~15份,柴胡10~15份,白芍10~15份,当归10~15份,玉米须10~15份,小蓟10~15份,虎杖10~15份,枸杞10~15份,女贞子10~20份,柏子仁10~20份,冬瓜皮10~20份,天花粉10~20份,莪术10~20份,墨旱莲10~20份,制首乌10~20份,车前子10~20份,鸡内金10~20份,生地10~20份,板蓝根10~20份。
3.根据权利要求1所述保肝利胆的大黄口服液,其特征在于,所述口服液中各种原料药的重量份数为:大黄10~30份,茵陈10~20份,茯苓10~20份,鱼腥草10~20份,柴胡10~20份,白芍10~20份,当归10~20份,玉米须10~20份,小蓟10~20份,虎杖10~20份,枸杞10~20份,女贞子10~15份,柏子仁10~15份,冬瓜皮10~15份,天花粉10~15份,莪术10~15份,墨旱莲10~15份,制首乌10~15份,车前子10~15份,鸡内金10~15份,生地10~15份,板蓝根10~15份。
4.一种如权利要求1~3中任一项所述保肝利胆的大黄口服液的制备方法,其特征在于,所述口服液的制备步骤包括:
a.大黄的制备,作为组分1;
b.将所述其余原料药放入乙醇中加热回流提取2次,作为组分2;
c.将上述两种提取液组分1和组分2合并,浓缩后加蜂蜜或糊精调和,消毒杀菌后制备成口服液装瓶。
5.根据权利要求4所述保肝利胆的大黄口服液的制备方法,其特征在于,所述步骤a中,在秋末茎叶枯萎或次春发芽前采挖,除去细根,刮去外皮,切瓣或段,绳穿成串干燥或直接干燥,然后将其浸泡占其质量10倍量的乙醇中1-2小时,然后放入提取罐加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.06的浸膏,加热浓缩至膏状,静置备用,成组分1备用。
6.根据权利要求4所述保肝利胆的大黄口服液的制备方法,其特征在于,所述步骤b中,将所述其余原料泡入占其质量10倍量乙醇中,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.06的浸膏,加热浓缩至膏状,静置备用,成组分2。
7.根据权利要求4所述保肝利胆的大黄口服液的制备方法,其特征在于,所述步骤c中,将组分1和组分2合并后,置入双效真空浓缩器中,浓缩至90℃时相对密度为1.36的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含0.1g生药量;浓缩后的膏剂加蜂蜜或糊精调和,紫外线消毒杀菌后装瓶。
8.一种如权利要求1~3中任一项所述保肝利胆的大黄口服液的制备方法,其特征在于,制备步骤还可以为:
a.将大黄制备成熟大黄,加水提取,作为组分1;
b.将大黄提取后残渣与所述其余原料药一起加水浸泡、提取2次作为组分2;
c.将组分1、组分2混合浓缩后加蜂蜜调和,紫外线消毒杀菌后装瓶。
9.根据权利要求8所述保肝利胆的大黄口服液的制备方法,其特征在于,所述步骤a中,在秋末茎叶枯萎或次春发芽前采挖,除去细根,刮去外皮,切瓣或段,绳穿成串干燥或直接干燥,取切成小块的生大黄,用黄酒拌匀,放蒸笼内蒸制,或置罐内密封,坐水锅中,隔水蒸透,取出晒干,按上法反复蒸制2~3次者,干燥成熟大黄,然后将干燥后的熟大黄片加水,然后放入提取罐加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.06的浸膏,作为组分1;所述步骤b中,将提取的大黄渣滓与所述其余原料一起放入占其质量5-10倍量水中,浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,将2次提取液合并静置,减压并浓缩至药液浓度为0.6g生药/mL,抽滤后,滤液的相对密度约为20℃时1.08;减压至0.03-0.08MPa,温度保持在60-80℃,浓缩至相对密度为1.20,温度至60℃-70℃的浸膏,作为组分2。
10.根据权利要求8所述保肝利胆的大黄口服液的制备方法,其特征在于,所述步骤c中,将组分1与组分2混合后放入减压浓缩罐内,减压回收乙醇,浓缩至药液浓度为0.1g生药/mL,抽滤至滤液的相对密度为20℃时1.06;上述滤液经体积为10L的大孔吸附树脂柱吸附后,用10倍树脂柱体积的去离子水或蒸馏水洗脱,再用5倍树脂柱体积的95%乙醇洗脱,收集乙醇洗脱液,去除溶剂,再调和蜂蜜,紫外线消毒杀菌后装瓶。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510657251.1A CN105169275A (zh) | 2015-10-12 | 2015-10-12 | 一种保肝利胆的大黄口服液及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510657251.1A CN105169275A (zh) | 2015-10-12 | 2015-10-12 | 一种保肝利胆的大黄口服液及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105169275A true CN105169275A (zh) | 2015-12-23 |
Family
ID=54892023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510657251.1A Pending CN105169275A (zh) | 2015-10-12 | 2015-10-12 | 一种保肝利胆的大黄口服液及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105169275A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106010853A (zh) * | 2016-05-19 | 2016-10-12 | 成都迈瑞斯特装饰材料有限公司 | 一种具有补骨强腰功效的黄酒的制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101104069A (zh) * | 2007-06-14 | 2008-01-16 | 王寿叶 | 治疗肝(胆)炎症的中药方剂 |
| CN102349990A (zh) * | 2011-10-18 | 2012-02-15 | 董洪海 | 一种治疗乙型肝炎的中药 |
-
2015
- 2015-10-12 CN CN201510657251.1A patent/CN105169275A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101104069A (zh) * | 2007-06-14 | 2008-01-16 | 王寿叶 | 治疗肝(胆)炎症的中药方剂 |
| CN102349990A (zh) * | 2011-10-18 | 2012-02-15 | 董洪海 | 一种治疗乙型肝炎的中药 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106010853A (zh) * | 2016-05-19 | 2016-10-12 | 成都迈瑞斯特装饰材料有限公司 | 一种具有补骨强腰功效的黄酒的制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102847063B (zh) | 一种治疗气血两虚血瘀型糖尿病足的中药组合物及其制备方法 | |
| CN105343625A (zh) | 一种排毒除湿利胆的蒲公英口服液及其制备方法 | |
| CN103520572A (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
| CN105496917A (zh) | 一种积雪草抗皱面霜及其制备方法 | |
| CN102000164B (zh) | 一种治疗银屑病的中药组合物及其制备方法 | |
| CN102988675B (zh) | 一种治疗慢性前列腺炎的中药组合物及其制备方法 | |
| CN103301267A (zh) | 一种治疗高血压和/或动脉粥样硬化的中药组合物及应用 | |
| CN102178781B (zh) | 一种治疗阴囊湿疹的中药组合物及其制备方法 | |
| CN105343593A (zh) | 一种降压降脂的夏枯草保健口服液及其制备方法 | |
| CN106237131A (zh) | 降脂减肥的蒲公英口服液制备方法及其口服液 | |
| CN105412697A (zh) | 一种清热除湿、保肝利胆的佩兰口服液及其制备方法 | |
| CN105435197A (zh) | 一种治疗桥本氏病的药物组合物及其制备方法 | |
| CN105169278A (zh) | 一种保肝利胆的蒲公英口服液及其制备方法 | |
| CN105233056A (zh) | 一种清热除湿、利胆排毒的大黄口服液及其制备方法 | |
| CN105169275A (zh) | 一种保肝利胆的大黄口服液及其制备方法 | |
| CN105616984A (zh) | 一种益母草去皱美容膏及其制备方法 | |
| CN105663700A (zh) | 抗皱美容膏制作方法及其美容膏 | |
| CN105169067A (zh) | 一种通便润肠的大黄口服液及其制备方法 | |
| CN105343516A (zh) | 一种治疗肝火上炎的夏枯草口服液及其制备方法 | |
| CN104983886A (zh) | 治疗便秘的中药制剂及制备方法 | |
| CN104840773A (zh) | 治疗椎动脉型颈椎病的中药组合物及制法 | |
| CN105169277A (zh) | 一种保肝利胆的栀子口服液及其制备方法 | |
| CN105998979A (zh) | 一种治疗肺肾阴虚型慢性咽炎的中药组合物及方法 | |
| CN105919918A (zh) | 一种缓解眼袋的小米草眼霜及其制备方法 | |
| CN105832585A (zh) | 中药抗皱面霜制作方法及其面霜 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151223 |
|
| RJ01 | Rejection of invention patent application after publication |